Brown Advisory’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.81M | Sell |
35,881
-344
| -0.9% | -$23.5K | ﹤0.01% | 658 |
|
|
2026
Q1 | $2.34M | Buy |
36,225
+355
| +1% | +$25K | ﹤0.01% | 643 |
|
|
2025
Q4 | $2.41M | Buy |
35,870
+905
| +3% | +$60.9K | ﹤0.01% | 641 |
|
|
2025
Q3 | $2.56M | Sell |
34,965
-92
| -0.3% | -$6.11K | ﹤0.01% | 620 |
|
|
2025
Q2 | $1.82M | Buy |
35,057
+224
| +0.6% | +$12.7K | ﹤0.01% | 672 |
|
|
2025
Q1 | $2.22M | Sell |
34,833
-5,032
| -13% | -$292K | ﹤0.01% | 619 |
|
|
2024
Q4 | $1.91M | Buy |
39,865
+19,002
| +91% | +$974K | ﹤0.01% | 661 |
|
|
2024
Q3 | $1.19M | Buy |
20,863
+19
| +0.1% | +$1.09K | ﹤0.01% | 745 |
|
|
2024
Q2 | $1.09M | Hold |
20,844
| – | – | ﹤0.01% | 751 |
|
|
2024
Q1 | $848K | Sell |
20,844
-116
| -0.6% | -$4.35K | ﹤0.01% | 819 |
|
|
2023
Q4 | $775K | Buy |
20,960
+149
| +0.7% | +$5.61K | ﹤0.01% | 831 |
|
|
2023
Q3 | $795K | Hold |
20,811
| – | – | ﹤0.01% | 792 |
|
|
2023
Q2 | $751K | Hold |
20,811
| – | – | ﹤0.01% | 812 |
|
|
2023
Q1 | $795K | Sell |
20,811
-20,602
| -50% | -$966K | ﹤0.01% | 813 |
|
|
2022
Q4 | $2.36M | Hold |
41,413
| – | – | ﹤0.01% | 582 |
|
|
2022
Q3 | $1.64M | Hold |
41,413
| – | – | ﹤0.01% | 605 |
|
|
2022
Q2 | $1.82M | Hold |
41,413
| – | – | ﹤0.01% | 584 |
|
|
2022
Q1 | $1.65M | Sell |
41,413
-121
| -0.3% | -$4.31K | ﹤0.01% | 620 |
|
|
2021
Q4 | $1.67M | Buy |
41,534
+102
| +0.2% | +$3.81K | ﹤0.01% | 626 |
|
|
2021
Q3 | $1.69M | Buy |
41,432
+19
| +0% | +$794 | ﹤0.01% | 602 |
|
|
2021
Q2 | $1.88M | Sell |
41,413
-20,990
| -34% | -$929K | ﹤0.01% | 584 |
|
|
2021
Q1 | $2.6M | Sell |
62,403
-37
| -0.1% | -$1.69K | ﹤0.01% | 562 |
|
|
2020
Q4 | $2.67M | Buy |
62,440
+108
| +0.2% | +$3.88K | ﹤0.01% | 501 |
|
|
2020
Q3 | $1.64M | Buy |
62,332
+26,302
| +73% | +$732K | ﹤0.01% | 532 |
|
|
2020
Q2 | $966K | Hold |
36,030
| – | – | ﹤0.01% | 604 |
|
|
2020
Q1 | $648K | Hold |
36,030
| – | – | ﹤0.01% | 635 |
|
|
2019
Q4 | $639K | Hold |
36,030
| – | – | ﹤0.01% | 718 |
|
|
2019
Q3 | $559K | Hold |
36,030
| – | – | ﹤0.01% | 726 |
|
|
2019
Q2 | $619K | Sell |
36,030
-74,500
| -67% | -$1.2M | ﹤0.01% | 715 |
|
|
2019
Q1 | $1.78M | Hold |
110,530
| – | – | 0.01% | 661 |
|
|
2018
Q4 | $1.62M | Hold |
110,530
| – | – | 0.01% | 636 |
|
|
2018
Q3 | $2.01M | Hold |
110,530
| – | – | 0.01% | 634 |
|
|
2018
Q2 | $1.86M | Hold |
110,530
| – | – | 0.01% | 635 |
|
|
2018
Q1 | $2.17M | Sell |
110,530
-40,917
| -27% | -$792K | 0.01% | 509 |
|
|
2017
Q4 | $3.07M | Sell |
151,447
-38,089
| -20% | -$700K | 0.01% | 470 |
|
|
2017
Q3 | $3.29M | Sell |
189,536
-10,907
| -5% | -$148K | 0.01% | 455 |
|
|
2017
Q2 | $2.57M | Buy |
200,443
+1,605
| +0.8% | +$21.4K | 0.01% | 499 |
|
|
2017
Q1 | $2.58M | Buy |
198,838
+22,391
| +13% | +$283K | 0.01% | 481 |
|
|
2016
Q4 | $1.74M | Sell |
176,447
-87,913
| -33% | -$963K | 0.01% | 524 |
|
|
2016
Q3 | $3.19M | Sell |
264,360
-2,500
| -0.9% | -$25.5K | 0.01% | 428 |
|
|
2016
Q2 | $2.3M | Buy |
266,860
+206,585
| +343% | +$2.04M | 0.01% | 470 |
|
|
2016
Q1 | $571K | Buy |
+60,275
| New | +$567K | ﹤0.01% | 682 |
|
Other funds holding HALO
Brown Advisory's HALO Position: Q2 2026 in Review
Brown Advisory reduced its Halozyme (HALO) stake by 0.95% in Q2 2026, selling an estimated $23.5K and leaving 35,881 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #658.
Brown Advisory first reported a position in HALO in Q1 2016 and has held it in 42 quarters since. The position peaked at $3.29M in Q3 2017. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Brown Advisory held 35,881 shares of Halozyme worth $2.81M as of Q2 2026.
- Brown Advisory sold 344 Halozyme shares in Q2 2026, an estimated $23.5K.
- Halozyme made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #658 holding.
- Brown Advisory first reported a position in Halozyme in Q1 2016 and has held it in 42 quarters since.
- Brown Advisory's Halozyme position peaked at $3.29M in Q3 2017.
- 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.